Explore by Category

New Myeloma Combo (carfilzomib/dara/dex) Submitted for FDA Approval

MYELOMA NEWS - February 12, 2020

A new combination of multiple myeloma therapies has been submitted for FDA approval this week. Janssen submitted the request to the FDA for the use of daratumum... Read More

New CAR T Therapy Target CD229 Shows Impact in Multiple Myeloma

MYELOMA NEWS - February 11, 2020

A CAR T therapy going after a new target, CD-229, is showing early promise for multiple myeloma patients. CAR T cell therapy is an exciting new technology in d... Read More

Good News for Myeloma Patients: Steadily Improving Outcomes With "Total Therapy"

MYELOMA NEWS - February 06, 2020

The most recent issue of the journal Blood Advances provides us, myeloma patients, with good news. The article presents long-term follow-up data of over 4,300 p... Read More

Reducing CAR T Side Effects in Multiple Myeloma

MYELOMA NEWS - January 30, 2020

New immunotherapies in myeloma called CAR T therapy use a patient's own genetically-engineered T cells to attack the tumor. This breakthrough therapy is making ... Read More

Sanofi and Sebia Develop New Monoclonal Protein Detection Test in Multiple Myeloma

MYELOMA NEWS - January 27, 2020

In myeloma, it is known that patients who are taking monoclonal antibodies that target CD38 can have "detectable" levels of a monoclonal protein, when those lev... Read More

Multiple Myeloma Treatment and Secondary Cancers

MYELOMA NEWS - January 23, 2020

It is fair to say that, from multiple myeloma chat groups, support groups, blogs, etc. we have heard or read stories (or, heaven forbid, from personal experienc... Read More

A Single T Cell Therapy for All Cancers? British Researchers Make a Key Discovery.

MYELOMA NEWS - January 20, 2020

Cardiff University researchers have discovered a new a new type of T cell that can kill a variety of cancers, with the hope of creating a general "one-size-fits... Read More

What is the Myeloma Crowd Research Initiative (MCRI)?

MYELOMA NEWS - January 16, 2020

  The Myeloma Crowd Research Initiative (MCRI) is a new approach to funding cancer research; combining the skill and knowledge of leading myeloma specialists ... Read More

ASH 2019: Chemotherapy Melflufen Moves Through Myeloma Clinical Trials

MYELOMA NEWS - January 16, 2020

Many myeloma patients are familiar with the chemotherapy called melphalan, which is regularly used as part of the stem cell transplant process. A Swedish compan... Read More

Myeloma Highlights From ASH: Jack Aiello's Super Summary

MYELOMA NEWS - January 15, 2020

According to myeloma patient advocate Jack Aiello (definitely not medically trained) (Glossary of terms are below) PREFACE This is my 14th year attending ASH... Read More

Will a Failed Alzheimers Drug Further Improve Anti-BCMA CAR-T in Multiple Myeloma?

MYELOMA NEWS - January 10, 2020

There already is much excitement in the multiple myeloma community about the possibility of FDA-approval for one or more anti-BCMA CAR-T products in the coming ... Read More

ASH 2019: Minimal Residual Disease as a New Clinical Trial End Point

MYELOMA NEWS - January 08, 2020

Minimal Residual Disease (MRD) testing is a way of testing how much disease is left after myeloma therapy. MRD testing is now being used more often in the clini... Read More

1Q Gain Multiple Myeloma is Sensitive to Specific Drug Targeting

MYELOMA NEWS - January 08, 2020

"High risk" multiple myeloma may not always be considered high risk if a specific treatment can be found for it.    In multiple myeloma, g... Read More

Thanks to our site sponsors:

Takeda Oncology Celgene Adaptive biotechnologies